iBio (IBIO) Cash from Financing Activities (2012 - 2026)

iBio (IBIO) has 15 years of Cash from Financing Activities data on file, last reported at $28.2 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 2548.54% year-over-year to $28.2 million in Q1 2026; TTM through Mar 2026 was $91.8 million, a 568.25% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, down 63.55% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $28.2 million, up from $8.8 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for IBIO reached as high as $46.7 million in Q3 2025 and fell as low as -$3.0 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $7.0 million across 5 years, with a median of $2.5 million in 2023.
• Across the five-year window, Cash from Financing Activities slumped 106.55% in 2024 and soared 28930.25% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$3.0 million in 2022, then soared by 231.57% to $4.0 million in 2023, then tumbled by 103.8% to -$152000.0 in 2024, then soared by 5879.61% to $8.8 million in 2025, then soared by 220.48% to $28.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $28.2 million in Q1 2026, $8.8 million in Q4 2025, and $46.7 million in Q3 2025.